Carla Vitorino is Assistant Professor at the Faculty of Pharmacy, University of Coimbra. in the Pharmaceutical Technology area and is an integrated researcher at the Coimbra Chemistry Centre, currently a part of the associate laboratory Institute of Molecular Sciences (IMS). Her research and development activities have been fundamentally directed towards three interrelated focal points: (i) Scientific: The primary emphasis here pertains to the formulation of more effective strategies in conjunction with drug nanodelivery systems, tailored to address multipurpose requisites within unmet medical needs. Specifically, she has been working on the application of nanotechnology in drug permeation enhancement strategies for transdermal, oral, and drug delivery systems to brain targeting. Under the projects she has coordinated and co-coordinated, she has contributed to the development of advanced nanotechnological formulations, specifically tailored for brain targeting in the context of tumor treatment and diagnosis. Through the integration of in silico-in vitro-in vivo approaches, she has fostered the development of new treatment strategies for brain tumor patients and improved diagnosis, establishing the bridge between pharmaceutical research and clinical practice. Alternative routes to access brain (e.g. intranasal administration) for delivering drugs in a more efficient way have also been explored. (ii) Industrial: This has been grounded on the systematic deployment of frameworks driven by a quality by design (QbD) philosophy, along with process analytical technology (PAT) tools. The central tenet lies in the application of structured approaches to the development of specific drug products, including but not limited to semi-solids and injectables. Concomitantly, in-line process control and monitoring mechanisms are incorporated. (iii) Regulatory: This has been directed to the development of analytical protocols, elaborated as surrogate modalities for clinical trials. These protocols, addressing in vitro methodologies, are designed to facilitate the bioequivalence assessment of generic topical drug products, thus holding relevance in regulatory contexts.